How to future-proof the analysis of host cell proteins in biopharma using microflow LC-MS/MS

The increasing prevalence of new expression systems in biomanufacturing, new modalities in biotherapeutics, and new analytical technologies such as LC-MS/MS, is likely to lead regulators towards the requirement for more HCP data from biopharma manufacturers.

This article addresses the issues and proposes a new way of securing a comprehensive, 4-dimensional digital record of HCP data for potential future requirement by regulatory bodies.

Download Article

Fill out the form and receive the article immediately

How we will use your data

We will use your email address to send you the link to the document. By signing up, you agree to our privacy policy and to receive 6-12 emails per year on protein analysis and our services. Topics may include case stories, webinars, blog posts, news about Alphalyse, conferences, and our services.

You can instantly opt out at any time by clicking the unsubscribe link at the bottom of any of the emails.